IL17A and psoriasis: Given the significant burden of cardiovascular disease and metabolic disease, to which systemic inflammation can be a major contributor, it is important to know whether successful treatment of psoriasis reduces systemic inflammation and cytokines that are present in both atherosclerosis and psoriasis, such as IL-17 [12].